Shares of CytomX Therapeutics (CTMX) were up 34.4% to $20.40 in premarket trading Monday after the South San Francisco, Calif.-based company and New York-based Bristol-Myers Squibb (BMY) on Monday announced they are expanding their collaboration to discover novel therapies that will include up to eight additional targets using CytomX's proprietary Probody platform. The original collaboration was signed in May 2014.
CytomX stock rockets 35% after deal with Amgen - http://www.marketwatch.com/story/cy...ith-amgen-2017-10-03?siteid=yhoof2&yptr=yahoo
